This cluster reflects routine post-vesting selling behavior rather than negative sentiment. Traders should monitor for continued selling beyond this cluster or changes in guidance as potential red flags. The lack of buying, however, limits any bullish readthrough.
VIR drugs
VIR drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Feb 23 $7.43entry
- T+1 · 9mo ago +27.73%α +26.99% · $9.49
- T+5 · 9mo ago +25.71%α +25.09% · $9.34
- T+20 · 8mo ago +18.98%α +22.92% · $8.84
- T+60 · 6mo ago +18.04%α +9.78% · $8.77
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Multiple top executives at Vir Biotechnology, including the CEO, CFO, and Chief Medical Officer, sold shares in a coordinated cluster over two days, totaling over $206,000 in sales. The same insiders also received stock awards totaling 450,000 shares, indicating a routine grant or vesting event. The sales appear to be part of a planned transaction, likely related to tax or diversification strategies following the award vesting.
Key Financial Metrics
Key Facts
- CEO Marianne De Backer sold $141,894 worth of shares, the largest individual sale.
- All four C-suite insiders sold shares at $7.4528 per share on 2026-02-23, immediately after receiving large stock awards on 2026-02-22.
- Total sales value: $205,159.35 across 27,662 shares.
- Insiders collectively received 450,000 shares via awards at $0 cost, consistent with vesting of prior grants.
- No open-market purchases were made; all activity was sales or awards.
Financial Impact
$205,159 in insider sales; no direct financial impact to company balance sheet.
Risk Factors
- Perception of insider pessimism if media or investors misinterpret sales as sentiment-driven.
- Potential for increased share supply in the market from ongoing executive selling.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CONTEXT: Insider Cluster Data (8 trades, 7d window) | cluster-VIR-1771978367193 |
Track record
36 reports on VIR
4 of 8 bullish or bearish reports moved the stock their way by T+5. Best: +29.79% at T+5 after the Nov 6, 2026 report. 5 of 9 went positive at some point.
Filters
- Nov 16, 2026today 424B5 Bearish 5/10 Entry price pending
- Nov 13, 20263d ago 8-K Bearish 5/10 Entry $9.92 Now $9.58 +3.43% settles Nov 23
- Nov 12, 20264d ago 424B5 Bearish 5/10 Entry $9.96 Now $9.58 +3.82% settles Nov 20
- Nov 12, 20264d ago S-3ASR Neutral 3/10 Entry $9.96 Now $9.58 −3.82% settles Nov 20
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $13.15 Now $9.58 −27.15% settles Nov 17
- Nov 9, 20267d ago 8-K Bullish 6/10 Entry $13.65 to $9.58 Now $9.58 −29.79% ▼ −29.79% −28.10% vs SPY
- Nov 6, 202610d ago SC 13D/A Bearish 5/10 Entry $13.65 to $9.58 Now $9.58 +29.79% ▲ +29.79% +28.10% vs SPY
- Nov 4, 202612d ago 8-K Neutral 5/10 Entry $11.02 to $12.12 Now $9.58 −13.07% ▲ +9.98% +6.69% vs SPY
- Nov 3, 202613d ago 144 Neutral 2/10 Entry $11.22 to $13.15 Now $9.58 −14.62% ▲ +17.20% +17.79% vs SPY
- Nov 2, 202614d ago 144 Neutral 1/10 Entry $11.00 to $13.65 Now $9.58 −12.91% ▲ +24.05% +23.97% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers